Explore

Trendline Trendline
Precision BioSciences to Discuss New Data on Gene Editing Therapy for Hepatitis B at Upcoming Webcast

Precision BioSciences to Discuss New Data on Gene Editing Therapy for Hepatitis B at Upcoming Webcast

Precision BioSciences to Discuss New Data on Gene Editing Therapy for Hepatitis B at Upcoming Webcast
Trendline Trendline
Obsidian Therapeutics to Present Positive Phase 2 Results for OBX-115 in Advanced Melanoma at ASCO Meeting

Obsidian Therapeutics to Present Positive Phase 2 Results for OBX-115 in Advanced Melanoma at ASCO Meeting

Obsidian Therapeutics to Present Positive Phase 2 Results for OBX-115 in Advanced Melanoma at ASCO Meeting
Trendline Trendline
Longeveron Outlines Strategic Shift and Key Priorities for 2026 in Stockholder Letter

Longeveron Outlines Strategic Shift and Key Priorities for 2026 in Stockholder Letter

Longeveron Outlines Strategic Shift and Key Priorities for 2026 in Stockholder Letter
Trendline Trendline
Savara Presents Long-Term Data on Molgramostim for Rare Lung Disease at ATS Conference

Savara Presents Long-Term Data on Molgramostim for Rare Lung Disease at ATS Conference

Savara Presents Long-Term Data on Molgramostim for Rare Lung Disease at ATS Conference
Trendline Trendline
Atossa Therapeutics Highlights Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy

Atossa Therapeutics Highlights Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy

Atossa Therapeutics Highlights Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy
Trendline Trendline
Beam Therapeutics Advances in Gene Editing for Alpha-1 Antitrypsin Deficiency

Beam Therapeutics Advances in Gene Editing for Alpha-1 Antitrypsin Deficiency

Beam Therapeutics Advances in Gene Editing for Alpha-1 Antitrypsin Deficiency
Trendline Trendline
Beam Therapeutics Advances DNA Editor BEAM-302 for Alpha-1 Antitrypsin Deficiency

Beam Therapeutics Advances DNA Editor BEAM-302 for Alpha-1 Antitrypsin Deficiency

Beam Therapeutics Advances DNA Editor BEAM-302 for Alpha-1 Antitrypsin Deficiency
Trendline Trendline
Lantern Pharma's LP-300 Trial for Never-Smokers with NSCLC Advances with FDA Support

Lantern Pharma's LP-300 Trial for Never-Smokers with NSCLC Advances with FDA Support

Lantern Pharma's LP-300 Trial for Never-Smokers with NSCLC Advances with FDA Support
Trendline Trendline
CEL-SCI Announces Key Developments in Multikine Cancer Treatment and Strategic Partnership

CEL-SCI Announces Key Developments in Multikine Cancer Treatment and Strategic Partnership

CEL-SCI Announces Key Developments in Multikine Cancer Treatment and Strategic Partnership
Trendline Trendline
Relay Therapeutics Achieves 60% Response Rate in Rare Disease Trial, Surpassing Novartis

Relay Therapeutics Achieves 60% Response Rate in Rare Disease Trial, Surpassing Novartis

Relay Therapeutics Achieves 60% Response Rate in Rare Disease Trial, Surpassing Novartis
Trendline Trendline
FDA Accepts sNDA and Grants Priority Review to AQNEURSA for Ataxia-Telangiectasia

FDA Accepts sNDA and Grants Priority Review to AQNEURSA for Ataxia-Telangiectasia

FDA Accepts sNDA and Grants Priority Review to AQNEURSA for Ataxia-Telangiectasia
Trendline Trendline
ImmunityBio's ANKTIVA Plus BCG Receives FDA Review for Expanded Bladder Cancer Treatment

ImmunityBio's ANKTIVA Plus BCG Receives FDA Review for Expanded Bladder Cancer Treatment

ImmunityBio's ANKTIVA Plus BCG Receives FDA Review for Expanded Bladder Cancer Treatment